GlassScriptPhysician profile
Kimberly A Nell
NPI 1720472319
$9,901.53
in general payments reported to CMS, 2019-2025
48 companies · $2,107 in 2025
The $2,107 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $907 · 2022: $1,793 · 2023: $1,963 · 2024: $3,131 · 2025: $2,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,480 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,479.99 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $441.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,489.89 | 2023-2025 | |
| Daiichi Sankyo INC. | $988.31 | 2021-2025 | Enhertu, Injectafer, Datroway |
| E.R. Squibb & Sons, L.L.C. | $933.54 | 2021-2025 | Opdivo, Opdualag, Augtyro |
| Incyte Corporation | $812.79 | 2021-2025 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $622.08 | 2021-2025 | Enhertu, Lynparza, Calquence |
| Eisai INC. | $597.82 | 2021-2025 | |
| Janssen Biotech, INC. | $556.93 | 2021-2025 | Darzalex, Tecvayli, Imbruvica |
| Celgene Corporation | $505.57 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Merck Sharp & Dohme LLC | $357.40 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Lilly USA, LLC | $339.98 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Astellas Pharma US INC | $288.80 | 2021-2025 | Padcev, Xospata, Vyloy |
| Gilead Sciences, INC. | $249.98 | 2022-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $223.38 | 2021-2025 | |
| Pfizer INC. | $176.47 | 2022-2025 | |
| Seagen INC. | $150.27 | 2021-2023 | Padcev, Tukysa, Adcetris |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $138.38 | 2022-2024 | Libtayo |
| Genmab U.S., INC. | $121.84 | 2021-2025 | Tivdak, Epkinly |
| Glaxosmithkline, LLC. | $104.56 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Array Biopharma INC | $101.42 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Pharmacosmos Therapeutics INC. | $75.19 | 2025 | Monoferric |
| Genzyme Corporation | $74.26 | 2021-2022 | |
| Stemline Therapeutics INC. | $70.58 | 2023-2025 | Orserdu |
| Takeda Pharmaceuticals U.S.A., INC. | $66.79 | 2022-2024 | Fruzaqla, Alunbrig |
| Tempus Ai, INC | $60.09 | 2024-2025 | Xt Cdx |
| Tersera Therapeutics LLC | $56.76 | 2021-2025 | Zoladex |
| Jazz Pharmaceuticals INC. | $55.40 | 2024-2025 | |
| Abbvie INC. | $52.40 | 2022 | |
| Springworks Therapeutics, INC. | $51.18 | 2025 | Ogsiveo |
| Geron Corporation | $51.03 | 2025 | Rytelo |
| Sobi, INC | $50.55 | 2023-2025 | |
| Immunocore Limited | $49.78 | 2024-2025 | Kimmtrak |
| Dendreon Pharmaceuticals LLC | $45.89 | 2024-2025 | Provenge |
| Kite Pharma, INC. | $40.50 | 2022-2023 | Yescarta |
| Novocure INC. | $39.27 | 2021-2024 | Optune |
| Pharmaessentia USA Corporation | $35.62 | 2025 | Besremi |
| Morphosys, US INC. | $33.89 | 2023 | Monjuvi |
| Emd Serono, INC. | $29.76 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $25.99 | 2021-2022 | |
| G1 Therapeutics, INC. | $24.84 | 2023 | Cosela |
| Alexion Pharmaceuticals, INC. | $21.21 | 2025 | Ultomiris |
| Aveo Pharmaceuticals, INC. | $19.28 | 2022 | |
| Genentech USA, INC. | $18.75 | 2025 | Polivy |
| Servier Pharmaceuticals LLC | $17.66 | 2025 | |
| Blueprint Medicines Corporation | $16.52 | 2021 | |
| Coherus Oncology, INC. | $16.18 | 2023 | |
| Taiho Oncology, INC. | $15.81 | 2023 | |
| Mirati Therapeutics, INC. | $13.92 | 2024 | Krazati |
| Amgen INC. | $13.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Nell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.